Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...
Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...
12don MSN
Shares of Summit Therapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage ...
Shares of Summit Therapeutics (NASDAQ: SMMT) rocketed as high as 75.2% Monday, before settling into a 57.5% gain as of 1:27 PM EDT. Aa an early-stage biotech, a potential blockbuster drug would be ...
Summit Therapeutics' ivonescimab shows a significant PFS improvement over pembrolizumab in NSCLC. Read why I'm bearish on ...
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $14 ...
Shares of Summit Therapeutics (NASDAQ: SMMT) recently jumped in response to positive clinical trial results for its experimental cancer therapy. Results of the phase 3 Harmoni-2 trial suggest ...
Instead of delivering two therapies, ivonescimab from Summit Therapeutics, IMM2510 from Instil Bio, and BNT327 from BioNTech are all bispecific antibodies that inhibit VEGF and the PD-1 checkpoint ...
Summit Therapeutics’ stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial
Shares of Summit Therapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage trial data showing that its experimental lung-cancer treatment topped ...
Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback